Clinical trial
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus…
NCT02477826 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT02477826 |
|---|---|
| Title | An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) |
| Official title | An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) |
| Acronym | CheckMate 227 |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Collaborators | Ono Pharmaceutical Co. Ltd Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Nivolumab, Ipilimumab, Carboplatin, Cisplatin, Gemcitabine, Pemetrexed, Paclitaxel |
| Enrollment | 2,747 |
| Start date | Aug 5, 2015 |
| Primary completion | Oct 25, 2024 |
| Completion | Oct 25, 2024 |
| First posted | Jun 23, 2015 |
| Last update posted | Oct 30, 2025 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czechia, Finland, France and 21 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: